본문 바로가기
KERD
논문KCI 등재

비호지킨 림프종에서 DNA Topoisomerase Iiα, Ki-67, p53및 p27 발현변화

Altered Expression of DNA Topoisomerase IIα, Ki-67, p53 and p27 in Non-Hodgkin’s Lymphoma

신동훈|강현정|김지연|이창훈|설미영|박도윤|김활웅|최경운|이경민
대한병리학회|2005.10|Journal of Pathology and Translational Medicine|제39권 제5호|pp. 332-337

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류병리학

초록

Abstract

Background : Topoisomerase II (TOPO II) is an enzyme that separates intertwined chromosomes during DNA synthesis by transiently breaking and joining DNA strands. The level of TOP II is one of the determinants of cellular sensitivity to anti-tumor drugs in non-Hodgkin’s lymphoma patients. The alpha form of TOPO II has been recently used as a marker of cellular proliferation. High levels of TOPO II are expressed in aggressive and proliferative tumors. Methods : This study was designed to evaluate the relationship between TOPO II expression and clinicopathological parameters including age, gender, the serum LDH level, the serum 2-microglobulin level and stage, or expressions, of Ki-67, p53 and p27, in non-Hodgkin’s lymphoma. We analyzed forty-one biopsied tissue specimens from patients with non-Hodgkin’s lymphoma. Results : The expression of TOPO II increased with the clinical stage and it was correlated with Ki-67 and p53 expressions. However, TOPO II expression did not have any significant correlation with age, gender, the serum LDH level, the serum 2-microglobulin level and the p27 expression. Conclusions : TOPO II expression is a useful marker of cellular proliferation and it may serve as a prognostic factor of a tumor’s progression and aggressiveness in non-Hodgkin’s lymphomas.

참고문헌 (30)

  1. "DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S", 50, pp.917~25 (1987)
  2. "DNA topoisomerase I and II in cancer chemotherapy:update and perspectives", 32, pp.103~8 (1993)
  3. "Topoisomerase II alpha and topoisomerase II beta genes:characterization and mapping to human chromosomes 17 and 3,respectively", 52, pp.231~4 (1992)
  4. "Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II inNIH-3T3 cells", 2, pp.209~14 (1991)
  5. "Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II", 28, pp.8154~60 (1989)
  6. "DNA topoisomerases poisons as antitumor drugs", 58, pp.351~75 (1989)
  7. "DNA topoisomerases:essential enzymes and lethal targets", 34, pp.191~218 (1994)
  8. "DNA damage-triggered apoptosis:critical role of DNA repair,double-strand breaks,cell proliferation and signaling", 66, pp.1547~54 (2003)
  9. "Relationship of p53,bcl-2,and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas", 89, pp.601~9 (1997)
  10. "Decreased levels of the cell-cycle inhibitor p27Kip 1 protein:prognostic implications in primary breast cancer", 3, pp.227~30 (1997)
  11. "Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas", 3, pp.231~4 (1997)
  12. "The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues", 75, pp.1340~6 (1997)
  13. "Differential immunohistochemical staining for DNA topoisomerase IIalpha and beta in human tissues and for DNA topoisomerase IIbeta in non-Hodgkin’s lymphomas", 10, pp.168~75 (1997)
  14. "Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas", 38, pp.45~53 (2001)
  15. "Topoisomerase IIalphamRNA and tumour cell proliferation in non-Hodgkin's lymphoma", 50, pp.22~6 (1997)
  16. "Topoisomerase IIalpha gene(TOP2A)amplification and deletion in cancer--more common than anticipated", 14, pp.309~13 (2003)
  17. "The prognostic significance of DNA topoisomerase II-alpha and p27", Kip-1 protein immunoexpression in oligodendrogliomas, pp.125, 892~1 8
  18. "Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer", 82, pp.99~104
  19. "Immunohistochemical staining for DNA topoisomerase I,DNA topoisomerase II-alpha and p53 in gastric carcinomas", 21, pp.1167~72 (2001)
  20. "Contribution of gene-specific lesions,DNA-replication-associated damage,and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells", 238, pp.155~67 (1998)
  21. "p53 gene mutations and rearrangements in non-Hodgkin’s lymphoma", 85, pp.718~24 (1999)
  22. "p53 protein expression in lymphomas and reactive lymphoid tissue", 166, pp.235~41 (1992)
  23. "Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53,p16,and p27", 159, pp.205~13 (2001)
  24. "The ccumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma", 86, pp.4587~93 (1995)
  25. "p53 mutations are associated with histologic transformation of follicular lymphoma", 82, pp.2289~95 (1993)
  26. "p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas", 87, pp.3351~9 (1996)
  27. "Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma", 337, pp.529~34 (1997)
  28. "Cyclin-dependentkinase inhibitor p27KIP1 in lymphoid tissue:p27KIP1 expressionis inversely proportional to the proliferative index", 151, pp.151~60
  29. "Topoisomerase IIalpha expression in mantle cell lymphoma:a marker of cell proliferation and a prognostic factor for clinical outcome", 18, pp.1200~6 (2004)
  30. "The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin’s lymphoma", 9, pp.1406~11 (2003), Clin Cancer Res

관련 논문AI추천

담낭암종에서의 p53, Heat Shock Protein 70과 TopoisomeraseIIα 의 발현김대철, 노미숙, 정진숙대한병리학회 · Journal of Pathology and Translational Medicine2006 · 제40권 제6호미만성 대세포 B 림프종에서 P53, BCL-2 단백 발현 및 세포증식지수와 국제예후지표와의 연관성 분석강창석, 김동철, 박경신, 심상인, 이교영, 이아원대한병리학회 · Journal of Pathology and Translational Medicine2003 · 제37권 제6호간내 담관암종에서의 p53, Rb, bcl-2 단백 발현과 Ki-67 표지지수와의 상관관계구미진, 김홍진, 윤성수, 최준혁대한병리학회 · Journal of Pathology and Translational Medicine2003 · 제37권 제3호World Health Organization/International Society of Urological Pathology 등급체계에 따른 방광 요로상피암종의 증식표지자로서 Ki-67 발현 및 세포자멸사와 비교한 DNA topoisomerase II- α의 발현 양상박언섭, 유재형, 이동기, 이태진대한병리학회 · Journal of Pathology and Translational Medicine2002 · 제36권 제5호유방암에서 색소원제자리부합화에 의한 HER-2/neu 종양유전자 증폭과 Topoisomerase II-α 의 면역조직화학적 발현권귀영, 김미경, 박언섭, 오형균, 유재형, 이태진대한병리학회 · Journal of Pathology and Translational Medicine2003 · 제37권 제1호조기 위암에서 림프절 전이와 p53, Bcl-2 단백 발현 및 Ki-67 표지지수의 상관관계심영란, 최준혁대한병리학회 · Journal of Pathology and Translational Medicine2002 · 제36권 제1호

이 간행물의 다른 논문 (11건)

유방암종에서 E2F4와 E2F2의 발현조현진, 김은영, 이미자pp. 301-306방사선요법으로 치료한 자궁목의 침윤성 편평세포암종에서 HIF-1α 단백 발현성순희, 서현숙, 심기남, 박혜숙, 정성애, 박혜영, 이시내, 김승철, 박수연, 이경은, 문혜성, 조민선, 유은선, 유권, 이경자pp. 307-312Mutational and Loss of Heterozygosity Analysis of the p53 and PTENTumor Suppressor Genes in Breast Carcinoma이영호, 박문일, 김헌수, 나선영, 서광선, 이생금pp. 313-319Survivin and Fas Ligand Expressions Are Correlated with AngiolymphaticTumor Spread in Medullary Thyroid Carcinoma채승완, 박성회, 김민경, 김한성, 손진희, 박성혜, 김어진, 주미pp. 320-325Immunohistochemical Analysis of Insular Carcinoma of the Thyroid Gland이경분, 민혜숙, 박성회, 정두현, 백진호pp. 326-331
원문 보기